AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28205322 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QWS-AI 2.0 mg
Number of subjects: 365
Study 28205322 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 365
Study 28205322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study 28205322 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QWS-AI
Number of subjects: 365
Study 28205322 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 365
Study 26297649 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 62
Study 26297649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 22452770 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful heat stimulation
Number of subjects: 0
Study 22452770 — intervention group
Group type: COMPARATOR
Intervention: Nonpainful warm stimulation
Number of subjects: 0
Study 21372444 — intervention group
Group type: COMPARATOR
Intervention: LAC (lansoprazole 30 mg + amoxicillin 750 mg + clarithromycin 200 mg bid for 1 week)
Number of subjects: 74
Study 21372444 — intervention group
Group type: COMPARATOR
Intervention: LAC2E (lansoprazole 30 mg bid + amoxicillin 750 mg bid + clarithromycin 200 mg bid + ecabet sodium 2 g bid for 1 week)
Number of subjects: 74
Study 21372444 — intervention group
Group type: EXPERIMENTAL
Intervention: LA2E (lansoprazole 30 mg bid + amoxicillin 750 mg bid + ecabet sodium 2 g bid for 2 weeks)
Number of subjects: 74
Study 19141090 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive devices during percutaneous coronary intervention (PCI)
Number of subjects: 5728
Study 19141090 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy devices
Number of subjects: 5728
Study 19141090 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive devices
Number of subjects: 5728
Study 17367324 — intervention group
Group type: EXPERIMENTAL
Intervention: Excised lesions
Number of subjects: 90
Study 17367324 — intervention group
Group type: COMPARATOR
Intervention: Prospective follow-up at 3-month intervals for at least 1 year (mean 6.8 months)
Number of subjects: 90
Study 14979943 — intervention group
Group type: EXPERIMENTAL
Intervention: One per cent silver nitrate gel
Number of subjects: 44
Study 14979943 — intervention group
Group type: COMPARATOR
Intervention: 0.1 per cent silver nitrate gel
Number of subjects: 44
Study 10929023 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT) after high-dose chemotherapy (BEAM regimen)
Number of subjects: 15
Study 10929023 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 15
Study 9382536 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant intra-arterial infusion chemotherapy (Epirubicin on Days 1, 3, 5, 7 + MPA 1,200 mg)
Number of subjects: 21
Study 9382536 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant intravenous chemotherapy
Number of subjects: 21
Study 8452102 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (20 to 200 mg/day)
Number of subjects: 0
Study 8452102 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 0
Study 8452102 — intervention group
Group type: COMPARATOR
Intervention: Control (no antiestrogen)
Number of subjects: 0
Study 3095698 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard influenza vaccine (V)
Number of subjects: 333
Study 3095698 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg/day (Al)
Number of subjects: 333
Study 3095698 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg/day (A2)
Number of subjects: 333
Study 3095698 — intervention group
Group type: COMPARATOR
Intervention: Placebo (VP)
Number of subjects: 333
Study 3095698 — intervention group
Group type: COMPARATOR
Intervention: Placebo (AP)
Number of subjects: 333
Study 31089818 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) combined with steroid therapy
Number of subjects: 57
Study 31089818 — intervention group
Group type: COMPARATOR
Intervention: Steroid therapy alone
Number of subjects: 57
Study 29737804 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm olein
Number of subjects: 120
Study 29737804 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 120
Study 26563670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5 μg
Number of subjects: 464
Study 26563670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 2.5 μg
Number of subjects: 464
Study 26563670 — intervention group
Group type: COMPARATOR
Intervention: Placebo Respimat
Number of subjects: 464
Study 25356053 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin for 5-7 days starting 6 hours after the operation
Number of subjects: 120
Study 25356053 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 120
Study 25356053 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 120
Study 22251332 — intervention group
Group type: EXPERIMENTAL
Intervention: Belbin team role groups
Number of subjects: 62
Study 22251332 — intervention group
Group type: COMPARATOR
Intervention: Non-Belbin control groups
Number of subjects: 62
Study 20236611 — intervention group
Group type: EXPERIMENTAL
Intervention: Soda commercials
Number of subjects: 51
Study 20236611 — intervention group
Group type: COMPARATOR
Intervention: Water commercials
Number of subjects: 51
Study 18616856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 0
Study 18616856 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy (PHT)
Number of subjects: 0
Study 15966959 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-ID
Number of subjects: 0
Study 15966959 — intervention group
Group type: COMPARATOR
Intervention: SCT-ID
Number of subjects: 0
Study 11835911 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (600 mg/6 ml)
Number of subjects: 50
Study 11835911 — intervention group
Group type: COMPARATOR
Intervention: Saline (6 ml)
Number of subjects: 50
Study 12063159 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline alone (50-200 mg)
Number of subjects: 707
Study 12063159 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) alone (10 sessions)
Number of subjects: 707
Study 12063159 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus IPT
Number of subjects: 707
Study 12063159 — intervention group
Group type: COMPARATOR
Intervention: Sertraline alone
Number of subjects: 707
Study 12063159 — intervention group
Group type: COMPARATOR
Intervention: IPT alone
Number of subjects: 707
Study 9701539 — intervention group
Group type: EXPERIMENTAL
Intervention: High formalization
Number of subjects: 72
Study 9701539 — intervention group
Group type: EXPERIMENTAL
Intervention: Low formalization
Number of subjects: 72
Study 9701539 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 72
Study 8602903 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total toothbrush
Number of subjects: 193
Study 8602903 — intervention group
Group type: COMPARATOR
Intervention: New Improved Crest Complete toothbrush
Number of subjects: 193
Study 8602903 — intervention group
Group type: COMPARATOR
Intervention: Reach Advanced Design toothbrush
Number of subjects: 193
Study 8602903 — intervention group
Group type: COMPARATOR
Intervention: Oral‐B Advantage toothbrush
Number of subjects: 193
Study 2645243 — intervention group
Group type: EXPERIMENTAL
Intervention: Kitecko ultrasonic conductor
Number of subjects: 100
Study 2645243 — intervention group
Group type: COMPARATOR
Intervention: Water path system (IV bag)
Number of subjects: 100
Study 31823937 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadpill (irbesartan 37.5 mg, amlodipine 1.25 mg, hydrochlorothiazide 6.25 mg, atenolol 12.5 mg)
Number of subjects: 21
Study 31823937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29165570 — intervention group
Group type: EXPERIMENTAL
Intervention: Active arm with charge display showing maximum allowable Medicare reimbursement rate for tests
Number of subjects: 0
Study 29165570 — intervention group
Group type: COMPARATOR
Intervention: Control arm without charge display
Number of subjects: 0
Study 29165570 — intervention group
Group type: EXPERIMENTAL
Intervention: Active arm
Number of subjects: 0
Study 29165570 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study 26116933 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-oscillatory stimulation during sleep (0.75Hz)
Number of subjects: 0
Study 26116933 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation during sleep
Number of subjects: 0
Study 23983248 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoterminal propeptide of type III procollagen/type 1 collagen telopeptide ratio ≤1
Number of subjects: 246
Study 23983248 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide >100 pg/mL
Number of subjects: 246
Study 23983248 — intervention group
Group type: EXPERIMENTAL
Intervention: LV ejection fraction at discharge (per 5% increment)
Number of subjects: 246
Study 23983248 — intervention group
Group type: EXPERIMENTAL
Intervention: High brain natriuretic peptide and aminoterminal propeptide of type III procollagen/type 1 collagen telopeptide ratio ≤1
Number of subjects: 246
Study 20878178 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g of alcohol per kg bodyweight (vodka and orange juice)
Number of subjects: 10
Study 20878178 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric, isovolumetric non-alcoholic beverage
Number of subjects: 10
Study 19091990 — intervention group
Group type: EXPERIMENTAL
Intervention: NeisVac-C (MCC conjugated to tetanus toxoid)
Number of subjects: 393
Study 19091990 — intervention group
Group type: EXPERIMENTAL
Intervention: Menjugate (MCC conjugated to CRM(197))
Number of subjects: 393
Study 19091990 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningitec (MCC conjugated to CRM(197))
Number of subjects: 393
Study 19091990 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediacel coadministered with NeisVac-C
Number of subjects: 393
Study 17050927 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diclofenac in 2.5% hyaluronan gel
Number of subjects: 20
Study 17050927 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive gel vehicle, hyaluronan)
Number of subjects: 20
Study 12628864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal CPAP
Number of subjects: 7
Study 12628864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal CPAP with oral device
Number of subjects: 7
Study 12628864 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral CPAP
Number of subjects: 7
Study 10683506 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at earpoint (Lu 1)
Number of subjects: 12
Study 10683506 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at thenar muscle (LI 4)
Number of subjects: 12
Study 10683506 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial needle insertion into skin overlying Hegu point
Number of subjects: 12
Study 9118652 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion at 10 micrograms/kg/min
Number of subjects: 14
Study 7681656 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly(I):poly(C12U) 600 mg
Number of subjects: 14
Study 7681656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7681656 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly(I):poly(C12U) 200 mg
Number of subjects: 14
Study 30922990 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg
Number of subjects: 0
Study 30922990 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 μg
Number of subjects: 0
Study 30922990 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (both doses)
Number of subjects: 0
Study 30922990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28982815 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐health module embedded in Collaborative Occupational healthcare (ECO)
Number of subjects: 220
Study 28982815 — intervention group
Group type: COMPARATOR
Intervention: Usual sickness guidance
Number of subjects: 220
Study 25444805 — intervention group
Group type: EXPERIMENTAL
Intervention: 2009-H1N1 vaccine + Placebo
Number of subjects: 805
Study 25444805 — intervention group
Group type: EXPERIMENTAL
Intervention: H1N1 vaccine + IIV3 + Placebo
Number of subjects: 805
Study 25444805 — intervention group
Group type: EXPERIMENTAL
Intervention: H1N1 vaccine + Placebo + IIV3
Number of subjects: 805
Study 25444805 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV3 + Placebo + H1N1
Number of subjects: 805
Study 25444805 — intervention group
Group type: COMPARATOR
Intervention: IIV3
Number of subjects: 805
Study 22841362 — intervention group
Group type: EXPERIMENTAL
Intervention: SP assessments with SP feedback and group discussion
Number of subjects: 0
Study 22841362 — intervention group
Group type: COMPARATOR
Intervention: SP assessments only
Number of subjects: 0
Study 21980993 — intervention group
Group type: COMPARATOR
Intervention: Dehydration in a warm environment (DE-W)
Number of subjects: 7
Study 21980993 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration in a thermoneutral environment (DE-T)
Number of subjects: 7
Study 21980993 — intervention group
Group type: COMPARATOR
Intervention: Euhydration in a warm environment (EU-W)
Number of subjects: 7
Study 21980993 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydration in a thermoneutral environment (EU-T)
Number of subjects: 7
Study 19164393 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute geriatric units
Number of subjects: 11
Study 17112849 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 197
Study 14975468 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 2457
Study 14975468 — intervention group
Group type: COMPARATOR
Intervention: Diabetes mellitus
Number of subjects: 2457
Study 11829043 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation training (PMRT) - 20-min set of audiotaped instructions for home practice.
Number of subjects: 18
Study 11829043 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned).
Number of subjects: 18
Study 9460399 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical Rating Scale (NRS)
Number of subjects: 116
Study 9460399 — intervention group
Group type: EXPERIMENTAL
Intervention: Word Descriptor Scale (WDS)
Number of subjects: 116
Study 7929921 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene ointment 0.005%
Number of subjects: 114
Study 7929921 — intervention group
Group type: COMPARATOR
Intervention: Fluocinonide ointment 0.05%
Number of subjects: 114
Study 3074457 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrate bismuthate (TDB)
Number of subjects: 100
Study 3074457 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 100
Study 29722841 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat complementary food group
Number of subjects: 64
Study 29722841 — intervention group
Group type: COMPARATOR
Intervention: Dairy complementary food group
Number of subjects: 64
Study 29722841 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 26936312 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Behavioral Assessment and Intervention Program
Number of subjects: 176
Study 26936312 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 176
Study 26535884 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 146
Study 26535884 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 146
Study 24308572 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based nutrition education
Number of subjects: 294
Study 24308572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral methods applied to improved eating
Number of subjects: 294
Study 19996786 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted sled (WS) group towing 10% body mass (n = 7)
Number of subjects: 20
Study 19996786 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted vest (WV) group loaded with 18.5% body mass (n = 6)
Number of subjects: 20
Study 19996786 — intervention group
Group type: COMPARATOR
Intervention: Unresisted (UR) active control group (n = 7)
Number of subjects: 20
Study 18476415 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES) applied from 30 min before anesthesia to the end of operation
Number of subjects: 50
Study 18476415 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES)
Number of subjects: 50
Study 18476415 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TAES)
Number of subjects: 50
Study 16645132 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary stroke team support at discharge
Number of subjects: 198
Study 16645132 — intervention group
Group type: COMPARATOR
Intervention: Standard aftercare (control)
Number of subjects: 198
Study 14702930 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy in outpatients (Group A)
Number of subjects: 124
Study 14702930 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy in in-patients (Group B)
Number of subjects: 124
Study 14702930 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall endoscopic sphincterotomy
Number of subjects: 124
Study 11239618 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 microg vaginally, administered at home 24 hours after mifepristone.
Number of subjects: 2747
Study 11239618 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 800 microg vaginally, administered at home 48 hours after mifepristone.
Number of subjects: 2747
Study 11239618 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 800 microg vaginally, administered at home 72 hours after mifepristone.
Number of subjects: 2747
Study 8866546 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Screening System (HSS)
Number of subjects: 22
Study 8866546 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil format
Number of subjects: 22
Study 1627763 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta administered intravenously (i.v.) three times a week for at least 12 weeks
Number of subjects: 36
Study 1627763 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta administered intravenously (i.v.) once a week
Number of subjects: 36
Study 1627763 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta administered subcutaneously (s.c.) once a week
Number of subjects: 36
Study 1627763 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta administered subcutaneously (s.c.) with two doses per week
Number of subjects: 36
Study 1627763 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous dosing two or three times a week
Number of subjects: 36
Study 1627763 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous dosing
Number of subjects: 36
Study 1627763 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dosing
Number of subjects: 36
Study 6485738 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% enflurane
Number of subjects: 20
Study 6485738 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7% isoflurane
Number of subjects: 20
Study 31544230 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 24 mg intravenous dexamethasone (DXM)
Number of subjects: 486
Study 31544230 — intervention group
Group type: EXPERIMENTAL
Intervention: Two consecutive doses of 24 mg intravenous dexamethasone (DXM)
Number of subjects: 486
Study 31544230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 486
Study 30762779 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-Kin visual feedback balance training system
Number of subjects: 56
Study 30762779 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait rehabilitation training
Number of subjects: 56
Study 28525303 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with diode laser 830 nm
Number of subjects: 213
Study 28525303 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 213
Study 28525303 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 213
Study 26019694 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic (900 mg powdered garlic)
Number of subjects: 18
Study 26019694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 24316697 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromelain 150mg per day for three days and 100mg on days 4 to 7
Number of subjects: 34
Study 24316697 — intervention group
Group type: COMPARATOR
Intervention: Placebo in the same dosage as Bromelain
Number of subjects: 34
Study 23023471 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching Barney cartoon (in Spanish or English) for younger children
Number of subjects: 0
Study 23023471 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching Tarzan cartoon (in Spanish or English) for older children
Number of subjects: 0
Study 23023471 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied no cartoon viewing)
Number of subjects: 0
Study 19720922 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor (240 microg/kg) plus G-CSF (10 microg/kg)
Number of subjects: 298
Study 19720922 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus G-CSF (10 microg/kg)
Number of subjects: 298
Study 17728532 — intervention group
Group type: EXPERIMENTAL
Intervention: Respimat SMI pH 2.7
Number of subjects: 32
Study 17728532 — intervention group
Group type: EXPERIMENTAL
Intervention: Respimat SMI pH 7.0
Number of subjects: 32
Study 17728532 — intervention group
Group type: COMPARATOR
Intervention: CFC-MDI
Number of subjects: 32
Study 17728532 — intervention group
Group type: EXPERIMENTAL
Intervention: Respimat SMI pH 3.4
Number of subjects: 32
Study 17728532 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 32
Study 15504287 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretory human interferon alpha-2a
Number of subjects: 0
Study 15504287 — intervention group
Group type: COMPARATOR
Intervention: Ordinary interferon
Number of subjects: 0